M.D. Anderson Cancer Center: Prostatic Neoplasms trials

The registry lists 116 Prostatic Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 20 are open to participants now and 25 have results posted.

Early Phase 1 3Phase 1 19Phase 2 55Phase 3 8Phase 4 1No phase 38(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cancer Prevention and Treatment Demonstration for Ethnic and Racial MinoritiesCompletedNCT00453661
• 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of ProstateTerminatedNCT00429338Not applicable
• Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyActive, not recruitingNCT00329043Phase 2
• Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008CompletedNCT00084825Phase 2
• Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate CancerCompletedNCT00082732Phase 1
• Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate CancerCompletedNCT00080808Phase 2
• Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone MetastasesTerminatedNCT00080782Phase 2
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone MetastasesCompletedNCT00080678Phase 2
• Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid TumorsCompletedNCT00078845Phase 2
• Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus MitoxantroneCompletedNCT00059631Phase 1
• Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate CarcinomaCompletedNCT00038246Phase 1/2
• Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00038194Phase 1
• Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate CancerCompletedNCT00038181Phase 2
• Intravenous Estramustine With Taxol in Hormone Refractory Prostate AdenocarcinomaCompletedNCT00038168Phase 1/2
• Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate CancerCompletedNCT00003084Phase 2
• Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate CancerCompletedNCT00002855Phase 3